NEW YORK, Feb. 18 (GenomeWeb News) - Abbott Laboratories will continue to use Compugen's Genecarta technology for analyzing novel drug targets, Compugen said today.

 

Under the extended agreement, which started in early 2003, Abbott will receive several updates of Compugen's Genecarta database.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.